Participants in the study will receive one of the two treatment regimens. The R-CODOX-M/R-IVAC treatment involves a series of medications given through injections or infusions, which are methods of delivering drugs directly into the bloodstream. The DA-EPOCH-R treatment also involves a combination of medications administered in a similar way. Some patients may receive a placebo as part of the study to help compare the effectiveness of the treatments. The study will monitor patients over a period of time to assess their response to the treatment and any side effects they may experience.

The trial aims to confirm whether the DA-EPOCH-R treatment can improve the two-year progression-free survival rate to 85% compared to the expected 70% for the R-CODOX-M/R-IVAC treatment. This means researchers are looking to see if patients can live longer without their disease worsening when treated with DA-EPOCH-R. The study will also look at other outcomes, such as overall survival, which is the time from the start of the study until death from any cause, and the occurrence of any severe side effects. The trial is expected to continue until 2026.

The purpose of this study is to evaluate how safe and effective this new treatment is for patients whose cancer has returned or has not responded to previous treatments. The study will be conducted in two phases. In the first phase, researchers will determine the best dose of MB-CART19.1 to use. In the second phase, they will assess how well the treatment works in reducing cancer cells in the body. Throughout the study, participants will receive the treatment and be monitored for any side effects and improvements in their condition.

Participants will receive the MB-CART19.1 treatment through an intravenous infusion, which means it will be delivered directly into the bloodstream. The study aims to find out if this approach can help control or eliminate the cancer, and how long any positive effects might last. The trial will also look at the overall health and survival of participants over time. Some participants may receive a placebo as part of the study to help compare the effects of the treatment. The study is expected to continue until the end of 2025.

Participants in the study will receive the treatment through an intravenous infusion, which means it is delivered directly into the bloodstream. The study will monitor the response of the cancer to the treatment, looking for signs of improvement such as a reduction in the size of the cancer or complete disappearance. The study will also track how long any positive effects last and the overall survival of participants. The trial is designed to gather information over a period of time to understand the benefits and any potential risks associated with the treatment.

In addition to the main treatment, other medications may be used to support the participants during the trial. These include dexamethasone, a corticosteroid that helps reduce inflammation, and mesna, which is used to protect the bladder from harmful effects of certain chemotherapy drugs. The study aims to provide valuable insights into the potential of brexucabtagene autoleucel as a treatment option for those with Burkitt Lymphoma, offering hope for improved outcomes in this challenging condition.